Showing results (91-100 of 697) with videos related to
Sort By:
Pageof 70
Diabetologia|July 1, 1986
Correction by insulin added in vitro of abnormal membrane fluidity of the erythrocytes from type 1 (insulin-dependent) diabetic patientsI Juhan-Vague, D Rahmani-Jourdheuil, Z Mishal, et al.Diabete & Metabolisme|July 1, 1987
Relationships between plasma insulin triglyceride, body mass index, and plasminogen activator inhibitor 1I Juhan-Vague, P Vague, M C Alessi, et al.Thrombosis and Haemostasis|April 30, 1981
Binding of 99mTc plasminogen on fibrinI Juhan-Vague, M F Calas, F Roux, et al.Journal of Cardiovascular Pharmacology|January 1, 1995
Leukocyte activation study during occlusive arterial disease of the lower limb: effect of pentoxifylline infusionC Fossat, D Fabre, Y Alimi, et al.Diabetes|August 3, 2000
Plasminogen activator inhibitor 1, transforming growth factor-beta1, and BMI are closely associated in human adipose tissue during morbid obesityM C Alessi, D Bastelica, P Morange, et al.Thrombosis and Haemostasis|March 30, 2000
Genetic polymorphisms and coronary artery disease in the south of FranceI Canavy, M Henry, P E Morange, et al.Arteriosclerosis, Thrombosis, and Vascular Biology|May 16, 2000
The A -844G polymorphism in the PAI-1 gene is associated with a higher risk of venous thrombosis in factor V Leiden carriersP E Morange, M Henry, D Tregouët, et al.Thrombosis and Haemostasis|February 11, 2000
Fluvastatin decreases soluble thrombomodulin in cardiac transplant recipientsP Ambrosi, M F Aillaud, G Habib, et al.American Journal of Clinical Pathology|August 10, 1999
Screening for identified and unidentified protein C pathway defects by the Agkistrodon contortrix venom test in consecutive patientsA Robert, M F Aillaud, V Eschwège, et al.Arteriosclerosis, Thrombosis, and Vascular Biology|September 9, 2000
Thrombin-activatable fibrinolysis inhibitor antigen levels and cardiovascular risk factorsI Juhan-Vague, J F Renucci, M Grimaux, et al.Pageof 70